High chitotriosidase and AGE levels in acromegaly: a case-control study.
Acromegaly
Advanced glycation end products
Chitotriosidase
High-sensitivity CRP
Malondialdehyde
YKL-40
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
11
04
2022
accepted:
10
10
2022
pubmed:
15
10
2022
medline:
16
3
2023
entrez:
14
10
2022
Statut:
ppublish
Résumé
Acromegaly is associated with oxidative stress and inflammation parameters. Chitotriosidase (CHITO) is a marker of macrophage activation and plays a pivotal role in the activation of inflammatory and immunological responses. Our study aimed to determine CHITO,YKL-40, advanced glycation end product (AGE), and high-sensitivity C-reactive protein (hsCRP) levels to investigate malondialdehyde (MDA), catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activities and to evaluate any association of these parameters with carotid intima media thickness (cIMT) in patients with controlled acromegaly. Thirty controlled acromegaly patients and 41 age- and sex-matched control cases were studied. We obtained demographic data, hormonal and metabolic parameters, and cIMT. CHITO activity was measured with the fluorometric method of Chamoles et al. YKL-40 and hsCRP levels were measured using ELISA. AGEs were measured based on spectrofluorimetric detection. GSH-Px activity was determined by a colorimetric assay. MDA, SOD, and catalase activities were determined in hemolysis. Higher CHITO, AGE, and hsCRP concentrations were observed in patients with acromegaly compared to controls. SOD levels were non-significantly higher in the acromegaly group, while catalase activities were lower in patients with acromegaly. Correlation analyses of CHITO, AGEs, YKL-40, hsCRP, MDA, catalase, GSH-Px, and SOD with metabolic, anthropometric, and laboratory parameters did not demonstrate any significant correlation (p > 0.05). There was no significant difference between groups with regard to cIMT levels. This is the first study investigating CHITO and AGE levels in patients with acromegaly. Serum CHITO, AGE, and hsCRP levels in acromegalic patients were significantly increased. It may be important to evaluate CHITO, AGE, and hsCRP levels in acromegalic patients who are already under cardiometabolic surveillance due to risk of developing cardiovascular disease.
Identifiants
pubmed: 36241955
doi: 10.1007/s42000-022-00409-3
pii: 10.1007/s42000-022-00409-3
doi:
Substances chimiques
Catalase
EC 1.11.1.6
C-Reactive Protein
9007-41-4
Chitinase-3-Like Protein 1
0
chitotriosidase
EC 3.2.1.-
Antioxidants
0
Superoxide Dismutase
EC 1.15.1.1
Glycation End Products, Advanced
0
Glutathione Peroxidase
EC 1.11.1.9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-69Subventions
Organisme : Ege Üniversitesi
ID : TGA-2021-23122
Informations de copyright
© 2022. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Références
Colao A, Merola B, Ferone D, Lombardi G (1997) Acromegaly. J Clin Endocrinol Metab 82:2777–2781
pubmed: 9284694
doi: 10.1210/jcem.82.9.4257
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152
pubmed: 14769829
doi: 10.1210/er.2002-0022
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95–102
pubmed: 8050136
doi: 10.1111/j.1365-2265.1994.tb03789.x
Schöfl C, Petroff D, Tönjes A, Grussendorf M, Droste M, Stalla G, Jaursch-Hancke C, Störmann S, Schopohl J (2017) Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry. Pituitary 20:635–642
pubmed: 28808855
doi: 10.1007/s11102-017-0827-5
Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP (2013) Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol 167:1712–1718
pubmed: 23219077
doi: 10.1016/j.ijcard.2012.11.109
Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, Wallaschofski H, Buchfelder M, Schöfl C (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162:879–886
pubmed: 20145047
doi: 10.1530/EJE-09-0945
Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V, Murphy LJ (2003) Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 58:736–742
pubmed: 12780751
doi: 10.1046/j.1365-2265.2003.01789.x
Østergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD (2002) YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 9:598–604
pubmed: 11986266
pmcid: 119997
Wang HL, Hsiao PC, Tsai HT, Yeh CB, Yang SF (2013) Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients. Int J Mol Sci 14:22817–22825
pubmed: 24256818
pmcid: 3856092
doi: 10.3390/ijms141122817
Kumar A, Zhang KYJ (2019) Human Chitinases: Structure, Function, and Inhibitor Discovery. Adv Exp Med Biol 1142:221–251
pubmed: 31102249
doi: 10.1007/978-981-13-7318-3_11
Karadag B, Kucur M, Isman FK, Hacibekiroglu M, Vural VA (2008) Serum chitotriosidase activity in patients with coronary artery disease. Circ J 72:71–75
pubmed: 18159103
doi: 10.1253/circj.72.71
Artieda M, Cenarro A, Gañán A, Jericó I, Gonzalvo C, Casado JM, Vitoria I, Puzo J, Pocoví M, Civeira F (2003) Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. Arterioscler Thromb Vasc Biol 23:1645–1652
pubmed: 12893688
doi: 10.1161/01.ATV.0000089329.09061.07
Kologlu T, Ucar SK, Levent E, Akcay YD, Coker M, Sozmen EY (2014) Chitotriosidase as a possible marker of clinically evidenced atherosclerosis in dyslipidemic children. J Pediatr Endocrinol Metab 27:701–708
pubmed: 24572981
doi: 10.1515/jpem-2013-0365
Ferreira AL, Salvadori DM, Nascimento MC, Rocha NS, Correa CR, Pereira EJ, Matsubara LS, Matsubara BB, Ladeira MS (2007) Tomato-oleoresin supplement prevents doxorubicin-induced cardiac myocyte oxidative DNA damage in rats. Mutat Res 631:26–35
pubmed: 17499013
doi: 10.1016/j.mrgentox.2007.04.003
Boero L, Cuniberti L, Magnani N, Manavela M, Yapur V, Bustos M, Gómez Rosso L, Meroño T, Marziali L, Viale L, Evelson P, Negri G, Brites F (2010) Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (Oxf) 72:654–660
pubmed: 19681912
doi: 10.1111/j.1365-2265.2009.03685.x
Del Rio D, Stewart AJ, Pellegrini N (2005) A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 15:316–328
pubmed: 16054557
doi: 10.1016/j.numecd.2005.05.003
Raj DS, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a nephrologist’s perspective. Am J Kidney Dis 35:365–380
pubmed: 10692262
doi: 10.1016/S0272-6386(00)70189-2
Mukherjee D, Yadav JS (2002) Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. Am Heart J 144:753–759
pubmed: 12422142
doi: 10.1067/mhj.2002.124865
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Group AC (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148
pubmed: 20410227
doi: 10.1210/jc.2009-2670
Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, Force AAT (2011) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly–2011 update: executive summary. Endocr Pract 17:636–646
pubmed: 21846619
doi: 10.4158/EP.17.4.636
Sözmen EY, Tanyalçin T, Onat T, Kutay F, Erlaçin S (1994) Ethanol induced oxidative stress and membrane injury in rat erythrocytes. Eur J Clin Chem Clin Biochem 32:741–744
pubmed: 7865612
Sözmen EY, Sözmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D, Ersöz B (2001) Antioxidant enzymes and paraoxonase show a co-activity in preserving low-density lipoprotein from oxidation. Clin Exp Med 1:195–199
pubmed: 11918278
doi: 10.1007/s102380100003
Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288–1292
pubmed: 8132768
pmcid: 294082
doi: 10.1172/JCI117084
Kalousová M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51:597–604
pubmed: 12511184
Committee ADAPP (2022) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care 45:S17–S38
doi: 10.2337/dc22-S002
Bastard JP, Grimaldi A, Jardel C, Porquet D, Bruckert E, Hainque B (1997) A simple index of insulin resistance. Diabetes Metab 23:87–88
pubmed: 9059773
Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS (2012) Mannheim carotid intima-media thickness and plaque consensus (2004–2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34:290–296
pubmed: 23128470
doi: 10.1159/000343145
Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191
pubmed: 17695343
doi: 10.3758/BF03193146
Korolenko TA, Cherkanova MS (2009) [Chitotriosidase of human macrophages and mammalian chitinases: biological functions and abnormalities in pathology]. Vestn Ross Akad Med Nauk 39-45.
Cetin Sanlialp S, Nar G, Senol H (2021) Clinical significance of chitotriosidase in outpatients with advanced heart failure. J Investig Med 69:736–741
pubmed: 33272933
doi: 10.1136/jim-2020-001595
Cutaș A, Drugan C, Roman G, Rusu A, Cătană CS, Achimaș-Cadariu A, Drugan T (2021) Evaluation of chitotriosidase and neopterin as biomarkers of microvascular complications in patients with type 1 diabetes mellitus. Diagnostics (Basel) 11(2):263
pubmed: 33567717
doi: 10.3390/diagnostics11020263
Majewski S, Tworek D, Szewczyk K, Kiszałkiewicz J, Kurmanowska Z, Brzeziańska-Lasota E, Jerczyńska H, Antczak A, Piotrowski WJ, Górski P (2019) Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 14:1611–1631
pubmed: 31413557
pmcid: 6660640
doi: 10.2147/COPD.S184097
Recklies AD, White C, Ling H (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365:119–126
pubmed: 12071845
pmcid: 1222662
doi: 10.1042/bj20020075
De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P (2001) YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 285:926–931
pubmed: 11467840
doi: 10.1006/bbrc.2001.5253
Ozkan C, Altinova AE, Cerit ET, Yayla C, Sahinarslan A, Sahin D, Dincel AS, Toruner FB, Akturk M, Arslan M (2015) Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 18:621–629
pubmed: 25500981
doi: 10.1007/s11102-014-0621-6
Verhelst J, Velkeniers B, Maiter D, Haentjens P, T’Sjoen G, Rietzschel E, Corvilain B, Abrams P, Nobels F, Abs R, Bex M (2013) Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur J Endocrinol 168:177–184
pubmed: 23132698
doi: 10.1530/EJE-12-0753
Boero L, Manavela M, Gómez Rosso L, Insua C, Berardi V, Fornari MC, Brites F (2009) Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol (Oxf) 70:88–95
pubmed: 19128365
doi: 10.1111/j.1365-2265.2008.03323.x
Andreassen M, Vestergaard H, Kristensen L (2007) Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf) 67:909–916
pubmed: 17727678
doi: 10.1111/j.1365-2265.2007.02986.x
Ilhan M, Turgut S, Turan S, Demirci Cekic S, Ergen HA, Korkmaz Dursun G, Mezani B, Karaman O, Yaylim I, Apak MR, Tasan E (2018) The assessment of total antioxidant capacity and superoxide dismutase levels, and the possible role of manganese superoxide dismutase polymorphism in acromegaly. Endocr J 65:91–99
pubmed: 29046499
doi: 10.1507/endocrj.EJ17-0300
Yarman S, Ozden TA, Gökkuşu C (2003) The evaluation of lipid peroxidation and acute effect of octreotide on lipid peroxidation in patients with active acromegaly. Clin Chim Acta 336:45–48
pubmed: 14500033
doi: 10.1016/S0009-8981(03)00328-0
Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN (2013) Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res 45:314–318
pubmed: 23093460
Brown-Borg HM, Rakoczy SG, Romanick MA, Kennedy MA (2002) Effects of growth hormone and insulin-like growth factor-1 on hepatocyte antioxidative enzymes. Exp Biol Med (Maywood) 227:94–104
pubmed: 11815672
doi: 10.1177/153537020222700203
Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, Lombardi G, Colao A (2002) Early vascular alterations in acromegaly. J Clin Endocrinol Metab 87:3174–3179
pubmed: 12107220
doi: 10.1210/jcem.87.7.8643